Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025

Rhea-AI Summary

Integrated BioPharma (OTCQX:INBP) reported its financial results for Q4 and fiscal year 2025. The company achieved Q4 revenue of $14.2 million, up 11.8% year-over-year, and full-year revenue of $54.3 million, an 8.0% increase from FY2024.

For FY2025, INBP reported net income of $808,000 ($0.03 per share), compared to $112,000 in FY2024. However, Q4 2025 saw a net loss of $0.2 million (-$0.01 per share), versus net income of $0.3 million in Q4 2024. The company's Contract Manufacturing Segment showed strong customer concentration, with two largest customers representing 84% of total revenue in FY2025, down from 90% in FY2024.

Positive

• Revenue increased 8.0% year-over-year to $54.3 million in FY2025
• Q4 2025 revenue grew 11.8% to $14.2 million
• FY2025 net income increased significantly to $808,000 from $112,000 in FY2024
• Customer base expansion reduced concentration risk from 90% to 84% for top two customers
• Operating income improved to $2.02 million in FY2025 from $251,000 in FY2024

Negative

• Q4 2025 resulted in a net loss of $0.2 million, compared to $0.3 million profit in Q4 2024
• High customer concentration with 84% of revenue from just two customers
• Significant increase in income tax expense to $1.25 million in FY2025 from $156,000 in FY2024

HILLSIDE, NJ / ACCESS Newswire / September 23, 2025 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2025.

Revenue for the quarter ended June 30, 2025 was $14.2 million compared to $12.7 million for the quarter ended June 30, 2024, an increase of $1.5 million or 11.8%. The Company had operating income of approximately $589,000 and $402,000 in the quarters ended June 30, 2025 and 2024, respectively.

Revenues for the fiscal year ended June 30, 2025 were $54.3 million compared to $50.3 million for the fiscal year ended June 30, 2024, an increase of $4.0 million or 8.0%. The Company had operating income for the fiscal year ended June 30, 2025 of approximately $0.6 million compared to operating income of $0.3 million for the fiscal year ended June 30, 2024.

For the quarter ended June 30, 2025, the Company had a net loss of approximately $0.2 million or $0.01 per share of common stock, compared with net income of $0.3 million or $0.01 per share of common stock for the quarter ended June 30, 2024. The Company's diluted net (loss) income per share of common stock for the quarters ended June 30, 2025 and 2024 were $(0.01) and $0.01 per share of common stock, respectively.

For the fiscal year ended June 30, 2025, the Company had net income of approximately $808,000 or $0.03 per share of common stock, compared with a net income of $112,000 or $0.00 per share of common stock for the fiscal year ended June 30, 2024. The Company's diluted net income per share of common stock for the fiscal years ended June 30, 2025 and 2024 were $0.03 and $0.00 per share of common stock, respectively.

"Our revenues increased by 8.0% in the fiscal year ended June 30, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 84% and 90% of total revenue in the fiscal year ended June 30, 2025 and 2024, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue," the Co-CEOs further stated.

A summary of our financial results for the three months and fiscal years ended June 30, 2025 and 2024 follows:

INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except share and per share amounts)
(unaudited)
		Three Months Ended								Fiscal Year Ended
		June 30,								June 30,
		2025				2024				2025				2024
Total revenue		$	14,175			$	12,746			$	54,353			$	50,317
Cost of sales			12,706				11,462				48,791				46,433
Gross profit			1,469				1,284				5,562				3,884
Selling and administrative expenses			880				882				3,542				3,633
Operating income			589				402				2,020				251
Other income, net			6				12				42				17
Income before income taxes			595				414				2,062				268
Income tax expense, net			773				146				1,254				156
Net (loss) income		$	(178	)		$	268			$	808			$	112
Net (loss) income per common share:
Basic		$	(0.01	)		$	0.01			$	0.03			$	0.00
Diluted		$	(0.01	)		$	0.01			$	0.03			$	0.00
Weighted average common shares outstanding:
Basic			30,622,045				30,099,610				30,295,655				30,066,003
Diluted			30,622,045				30,702,683				31,168,372				30,873,681

About Integrated BioPharma Inc. (INBP)

Integrated BioPharma, Inc. ("INBP") is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Further information is available at ir.ibiopharma.com.

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause the results of INBP to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements generally are identified by the words "expects," "anticipates," believes," intends," "estimates," "should," "would," "strategy," "plan" and similar expressions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements and are not guarantees of future performance. Such statements speak only as of the date hereof, are subject to change and should not be relied upon for investment purposes. INBP undertakes no obligation to revise or update any statements for any reasons. The risks, uncertainties and assumptions include, among others, changes in general economic and business conditions; loss of market share through competition; introduction of competing products by other companies; the timing of regulatory approval and the introduction of new products by INBP; changes in industry capacity; pressure on prices from competition or from purchasers of INBP's products; regulatory changes in the pharmaceutical manufacturing industry and nutraceutical industry; regulatory obstacles to the introduction of new technologies or products that are important to INBP; availability of qualified personnel; the loss of any significant customers or suppliers; inflation, including inflationary pressures from any tariffs, and tightened labor markets; our ability to expand our customer base and other risks and uncertainties described in the section entitled "Risk Factors" in INBP's most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. Accordingly, INBP cannot give assurance that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of INBP.

Contact: Dina Masi, CFO
Integrated BioPharma, Inc.
investors@ibiopharma.com
888.319.6962

SOURCE: Integrated BioPharma, Inc.

View the original press release on ACCESS Newswire

FAQ

What were Integrated BioPharma's (INBP) earnings per share for fiscal year 2025?

INBP reported earnings of $0.03 per share for fiscal year 2025, compared to $0.00 per share in fiscal year 2024.

How much revenue did INBP generate in Q4 2025?

INBP generated revenue of $14.2 million in Q4 2025, representing an 11.8% increase from $12.7 million in Q4 2024.

What was INBP's customer concentration in fiscal year 2025?

INBP's two largest customers in the Contract Manufacturing Segment accounted for 84% of total revenue in fiscal year 2025, down from 90% in fiscal year 2024.

What was Integrated BioPharma's operating income for fiscal year 2025?

INBP reported operating income of $2.02 million for fiscal year 2025, significantly higher than the $251,000 reported in fiscal year 2024.

How did INBP perform in Q4 2025 compared to Q4 2024?

In Q4 2025, INBP reported revenue growth of 11.8% to $14.2 million, but recorded a net loss of $0.2 million compared to a net income of $0.3 million in Q4 2024.